As the panelists discuss cancer immunotherapy, Daniel J. George, MD, recognizes the tremendous amount of progress made in the development of immunotherapy agents. Dr George explains that as immunotherapy continues to evolve, the therapy option is now branching out to treat an entire host of tumors for all different stages of cancer, whereas in the past, immunotherapy played a role mainly in bladder cancer.
Jeffrey Weber, MD, PhD, discusses how immunotherapy agents can be divided into 4 or 5 categories. Vaccines such as ipilmumab are among the most promising.
As exciting as the future looks, Michael Kolodziej, MD, is concerned about the cost of cancer immunotherapy drugs. Dr Kolodziej explains that these new therapies are very expensive, and is further concerned about the costs, as therapies are sometimes combined.
Dr George argues that the expense of these agents forces patients and their providers to stick to FDA-labeled treatments, whereas in the past, patients were treated off-label in certain instances. It is now too expensive to go off-label, and it is important that treatment decisions be data driven rather than focused on cost.
Unfortunately, Dr Weber argues, not all data are reflected on a drug’s label or package insert.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More